Exelixis Inc EXEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
-
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
-
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
-
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
-
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
Trading Information
- Previous Close Price
- $53.50
- Day Range
- $53.06–53.87
- 52-Week Range
- $33.76–53.93
- Bid/Ask
- $51.74 / $53.45
- Shares Outstanding
- 251.36M
- Market Cap
- $13.35B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 16.02
- Price/Sales
- 6.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 8.19%
Company Profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,077
- Website
- https://www.exelixis.com
Valuation
|
Metric
|
EXEL
|
|---|---|
Price/Earnings (Normalized) | 16.02 |
Price/Book Value | 7.01 |
Price/Sales | 6.23 |
Price/Cash Flow | 13.05 |
Price/Earnings
EXEL
Financial Strength
|
Metric
|
EXEL
|
|---|---|
Quick Ratio | 2.98 |
Current Ratio | 3.26 |
Interest Coverage | — |
Quick Ratio
EXEL
Profitability
|
Metric
|
EXEL
|
|---|---|
Return on Assets (Normalized) | 33.49% |
Return on Equity (Normalized) | 44.26% |
Return on Invested Capital (Normalized) | 38.36% |
Return on Assets
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ykhprqbk | Pjlvvtw | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sdsbsmr | Mvwkvx | $64B | |||
| argenx SE ADR
ARGX
| Gphsmby | Hzqw | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zyxpnbpk | Nzkkwv | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Zzcxyhlnq | Bsffk | $24B | |||
| BioNTech SE ADR
BNTX
| Qhlcqcvz | Wgtn | $23B | |||
| Incyte Corp
INCY
| Kxbyljft | Gmdm | $22B | |||
| Moderna Inc
MRNA
| Blspmnzz | Kkpw | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Bmnyxxzd | Tpq | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Qwpxjdl | Nhsq | $13B |
United States